HCA Healthcare reported a 4% increase in its revenues to $15.59bn in Q1 2023, compared with $14.94bn in Q1 2022.

The net income attributable to HCA Healthcare stood at $1.36bn, or $4.85 per diluted share, an increase of 6.8% from $1.27bn, or $4.14 per diluted share, in Q1 2022.

The hospital chain posted losses on sales of facilities of $15m, or $0.08 per diluted share, in Q1 2023. In the same period in 2022, it reported gains on sales of facilities of $10m, or $0.02 per diluted share.

HCA Healthcare recorded $145m of revenues, or $0.40 per diluted share, associated with resolving some disputed claims from previous years with a commercial payer during the quarter.

Its adjusted EBITDA stood at $3.17bn in Q1 2023, compared with $2.94bn in Q1 2022.

Same facility admissions grew by 4.4%, while same facility equivalent admissions rose by 7.5% in Q1 2023, as against the prior year period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the quarter, the hospital saw same-facility emergency room visits grow by 10.3%, same-facility inpatient surgeries increase by 3.6% and same-facility outpatient surgeries grow by 5.1%.

Same facility revenue per equivalent admission fell 2.3% in Q1 2023 compared with the corresponding quarter of last year.

The year-over-year comparison of same-facility revenue per equivalent admission was affected by higher Covid-19 volumes and reimbursement in the previous year.

In Q1 2023, Covid-19 represented 3.1% of same-facility admissions, while the figure was 9.7% in the prior-year quarter.

As of 31 March 2023, the company’s balance sheet had recorded cash and cash equivalents of $842m, a total debt of $38.85bn, and total assets of $52.71bn.

Capital expenditures totalled $1.19bn, without including acquisitions.

Cash flows from operating activities in the latest quarter totalled $1.803bn, compared with $1.34bn in Q1 2022.

The company repurchased 3.340 million shares of its common stock at a cost of $846m in Q1 2023.

HCA Healthcare’s latest 2023 guidance range as of 21 April 2023 estimates revenue to be in the range of $62.5bn–$64.5bn and EPS (diluted) to be in the range of $17.25–18.55 per diluted share as against revenues of $61.5bn–63.5bn and $16.40–17.60 per diluted share in the previous 2023 guidance range as of 27 January 2023.